{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:44:18Z","timestamp":1789753458440,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009473","name":"University of Malaga","doi-asserted-by":"publisher","award":["PPRO-B4\\u20132024\\u2013010"],"award-info":[{"award-number":["PPRO-B4\\u20132024\\u2013010"]}],"id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016658","name":"Plan Nacional sobre Drogas","doi-asserted-by":"publisher","award":["EXP2022\/008766"],"award-info":[{"award-number":["EXP2022\/008766"]}],"id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020\\u2013114392RB-I00\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020\\u2013114392RB-I00\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118170","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:37:26Z","timestamp":1747341446000},"page":"118170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Galanin(1\u221215) and Naltrexone: A novel approach for alcohol use disorder in rats, involving the mesolimbic system"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-2632","authenticated-orcid":false,"given":"Marta","family":"Flores-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-7532","authenticated-orcid":false,"given":"Noelia","family":"Cantero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pedro","family":"Pineda-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7523-7304","authenticated-orcid":false,"given":"Amel","family":"Moh-Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-5674","authenticated-orcid":false,"given":"Antonio","family":"Flores-Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4613-9430","authenticated-orcid":false,"given":"Zaida","family":"D\u00edaz-Cabiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-5506","authenticated-orcid":false,"given":"Carmelo","family":"Mill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2025.118170_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopha.2025.118170_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-031323-115847","article-title":"Alcohol use disorder treatment: problems and solutions","volume":"64","author":"Koob","year":"2024","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2025.118170_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuroscience.2012.08.018","article-title":"Moderate drinking? Alcohol consumption significantly decreases neurogenesis in the adult hippocampus","volume":"224","author":"Anderson","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.118170_bib4","series-title":"Global Status Report on Alcohol and Health 2018","author":"WHO","year":"2024"},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.35946\/arcr.v39.1.02","article-title":"Adolescent binge drinking","volume":"39","author":"Chung","year":"2018","journal-title":"Alcohol Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118170_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(20)30088-8","article-title":"Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis?","volume":"5","author":"Clay","year":"2020","journal-title":"Lancet Public Health"},{"issue":"4","key":"10.1016\/j.biopha.2025.118170_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/dar.13074","article-title":"Alcohol use in times of the COVID 19: Implications for monitoring and policy","volume":"39","author":"Rehm","year":"2020","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.biopha.2025.118170_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113706","article-title":"Increased mood disorder symptoms, perceived stress, and alcohol use among college students during the COVID-19 pandemic","volume":"296","author":"Charles","year":"2021","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118170_bib9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/dar.13446","article-title":"Changes in alcohol use during the COVID-19 pandemic in Europe: a meta-analysis of observational studies","volume":"41","author":"Kilian","year":"2022","journal-title":"Drug Alcohol Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2025.118170_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/JCP.0b013e3182726764","article-title":"A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder","volume":"32","author":"Witte","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118170_bib12","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/j.1530-0277.2007.00510.x","article-title":"Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin","volume":"31","author":"Schneider","year":"2007","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.118170_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/acer.13076","article-title":"Serotonin's complex role in alcoholism: implications for treatment and future research","volume":"40","author":"Marcinkiewcz","year":"2016","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"12","key":"10.1016\/j.biopha.2025.118170_bib14","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1097\/01.ALC.0000148099.12344.C8","article-title":"Galanin microinjection in the third ventricle increases voluntary ethanol intake","volume":"28","author":"Lewis","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0741-8329(04)00097-7","article-title":"Ethanol intake is increased by injection of galanin in the paraventricular nucleus and reduced by a galanin antagonist","volume":"33","author":"Rada","year":"2004","journal-title":"Alcohol"},{"issue":"12","key":"10.1016\/j.biopha.2025.118170_bib16","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s00018-008-8151-x","article-title":"Galanin and addiction","volume":"65","author":"Picciotto","year":"2008","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00213-011-2515-x","article-title":"Galanin negatively modulates opiate withdrawal via galanin receptor 1","volume":"220","author":"Holmes","year":"2012","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118170_bib18","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1523\/JNEUROSCI.2442-16.2016","article-title":"Functional \u03bc-opioid-galanin receptor heteromers in the ventral tegmental area","volume":"37","author":"Moreno","year":"2017","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118170_bib19","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI126912","article-title":"Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids","volume":"129","author":"Cai","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbrc.2014.08.061","article-title":"Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex","volume":"452","author":"Borroto-Escuela","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu064","article-title":"A role for galanin N-terminal fragment (1-15) in anxiety- and depression-related behaviors in rats","volume":"18","author":"Mill\u00f3n","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118170_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0269881119844188","article-title":"Role of the galanin N-terminal fragment (1-15) in anhedonia: involvement of the dopaminergic mesolimbic system","volume":"33","author":"Mill\u00f3n","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/adb.12582","article-title":"Central administration of galanin N-terminal fragment 1-15 decreases the voluntary alcohol intake in rats","volume":"24","author":"Mill\u00f3n","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.biopha.2025.118170_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113508","article-title":"Galanin N-terminal fragment (1-15) reduces alcohol seeking and alcohol relapse in rats: involvement of mesocorticolimbic system","volume":"153","author":"Cantero-Garc\u00eda","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020412","article-title":"The combination of galanin (1-15) and escitalopram in rats suggests a new strategy for alcohol use disorder comorbidity with depression","volume":"10","author":"Cantero-Garc\u00eda","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1530-0277.2008.00830.x","article-title":"Early social isolation in male Long-Evans rats alters both appetitive and consummatory behaviors expressed during operant ethanol self-administration","volume":"33","author":"McCool","year":"2009","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pbb.2008.11.003","article-title":"The runway model of drug self-administration","volume":"91","author":"Ettenberg","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1369-1600.2006.00012.x","article-title":"Behavioural assessment of drug reinforcement and addictive features in rodents: an overview","volume":"11","author":"Sanchis-Segura","year":"2006","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/adb.12521","article-title":"Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration","volume":"23","author":"Lebourgeois","year":"2018","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1369-1600.2009.00192.x","article-title":"Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes","volume":"15","author":"Leeman","year":"2010","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib31","first-page":"77","article-title":"Animal models in alcohol research","volume":"24","author":"Tabakoff","year":"2000","journal-title":"Alcohol Res. Health"},{"issue":"3","key":"10.1016\/j.biopha.2025.118170_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.ALC.0000057943.57330.AB","article-title":"Preclinical and clinical studies on naltrexone: what have they taught each other?","volume":"27","author":"Froehlich","year":"2003","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.biopha.2025.118170_bib33","first-page":"217","article-title":"Advances in the use of naltrexone: an integration of preclinical and clinical findings","volume":"16","author":"Malley","year":"2003","journal-title":"Recent Dev. Alcohol"},{"issue":"6","key":"10.1016\/j.biopha.2025.118170_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"B. Ritson, A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib35","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.4088\/JCP.13m08934","article-title":"Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety","volume":"76","author":"O'Malley","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118170_bib36","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/adb.12425","article-title":"Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies","volume":"22","author":"Hendershot","year":"2017","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118170_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","article-title":"Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial","volume":"22","author":"Kranzler","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118170_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.biopha.2025.118170_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.18773\/austprescr.2015.063","article-title":"Naltrexone and liver disease","volume":"38","author":"McDonough","year":"2015","journal-title":"Aust. Prescr."},{"issue":"8","key":"10.1016\/j.biopha.2025.118170_bib40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.20230488","article-title":"Overview of alcohol use disorder","volume":"180","author":"Kranzler","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.25712","article-title":"Improving symptom management for people with amyotrophic lateral sclerosis","volume":"57","author":"Nicholson","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.biopha.2025.118170_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.npep.2017.01.004","article-title":"The neuropeptides Galanin and Galanin(1-15) in depression-like behaviours","volume":"64","author":"Mill\u00f3n","year":"2017","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopha.2025.118170_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neuropharm.2017.03.010","article-title":"Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression","volume":"118","author":"Flores-Burgess","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118170_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pbb.2014.03.006","article-title":"Stimulant and motivational effects of alcohol: lessons from rodent and primate models","volume":"122","author":"Brabant","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2025.118170_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.alcohol.2015.10.003","article-title":"Dose-dependent effects of alcohol administration on behavioral profiles in the MCSF test","volume":"50","author":"Karlsson","year":"2016","journal-title":"Alcohol"},{"issue":"4","key":"10.1016\/j.biopha.2025.118170_bib46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41386-018-0271-x","article-title":"Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition","volume":"44","author":"Browne","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pharmthera.2004.06.002","article-title":"The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement","volume":"103","author":"Gonzales","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118170_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.1992.tb25966.x","article-title":"Neural mechanisms of drug reinforcement","volume":"654","author":"Koob","year":"1992","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118170_bib50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118170_bib51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","article-title":"Opioids excite dopamine neurons by hyperpolarization of local interneurons","volume":"12","author":"Johnson","year":"1992","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118170_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/026988119801200108","article-title":"A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use","volume":"12","author":"Di Chiara","year":"1998","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2025.118170_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/bs.pbr.2015.07.030","article-title":"Opioid neuroscience for addiction medicine: from animal models to FDA approval for alcohol addiction","volume":"223","author":"Berrettini","year":"2016","journal-title":"Prog. Brain Res."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118170_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-8993(99)01476-6","article-title":"Centrally administered galanin blocks morphine place preference in the mouse","volume":"831","author":"Zachariou","year":"1999","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118170_bib55","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.npp.1301579","article-title":"Galanin protects against behavioral and neurochemical correlates of opiate reward","volume":"33","author":"Hawes","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118170_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106322","article-title":"Preferential Gs protein coupling of the galanin Gal","volume":"182","author":"De Oliveira","year":"2022","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.biopha.2025.118170_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fendo.2012.00127","article-title":"On the existence and function of galanin receptor heteromers in the central nervous system","volume":"3","author":"Fuxe","year":"2012","journal-title":"Front Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118170_bib58","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1007\/s00429-015-1180-y","article-title":"Galanin (1-15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system","volume":"221","author":"Mill\u00f3n","year":"2016","journal-title":"Brain Struct. Funct."},{"issue":"4","key":"10.1016\/j.biopha.2025.118170_bib59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ijnp\/pyab089","article-title":"Galanin (1-15) Enhances the behavioral effects of fluoxetine in the olfactory bulbectomy rat, suggesting a new augmentation strategy in depression","volume":"25","author":"Flores-Burgess","year":"2022","journal-title":"Int J. Neuropsychopharmacol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118170_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910848","article-title":"Galanin(1-15) potentiates the antidepressant-like effects induced by escitalopram in a rat model of depression","volume":"22","author":"Garc\u00eda-Dur\u00e1n","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118170_bib61","article-title":"Z. D\u00edaz-Cabiale, A new augmentation strategy against depression combining SSRIs and the N-terminal fragment of galanin (1-15)","author":"Flores-Burgess","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118170_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111191","article-title":"A new pharmacological strategy against treatment-resistant depression","volume":"136","author":"Pineda-G\u00f3mez","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:55:59Z","timestamp":1778630159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":62,"alternative-id":["S0753332225003646"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118170","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galanin(1\u221215) and Naltrexone: A novel approach for alcohol use disorder in rats, involving the mesolimbic system","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118170"}}